After Apellis deal, Biogen looks to fill early-stage pipeline
Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and research, because that part ...
April 29, 2026 11:15 AM EDTUpdated 12:58 PM DealsR&D After Apellis deal, Biogen looks to fill early-stage pipeline Lei Lei Wu News Reporter Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we’re going to be … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that